Novartis (NVS) announced that the World Health Organization, or WHO, has prequalified Coartem Baby, the first and only antimalarial developed specifically for newborns and young infants weighing from two to five kilograms. The decision is a step towards enabling access through public sector procurement. Coartem Baby is also known as Riamet Baby in some countries and was developed in collaboration with Medicines for Malaria Venture.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVS:
- Trump names Erica Schwartz CDC Director
- Trump Trade: White House launches space nuclear initiative
- Drugmakers raised prices on hundreds of drugs, NBC News reports
- 3 Best Vanguard Dividend ETFs for Reliable Passive Income in 2026
- Novartis CEO to join Anthropic board, WSJ reports